Neoadjuvant Endocrine Therapy: Who Benefits Most?

Julie Grossman, Cynthia Ma, Rebecca Aft

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor–positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor–positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.

Original languageEnglish
Pages (from-to)121-140
Number of pages20
JournalSurgical Oncology Clinics of North America
Issue number1
StatePublished - Jan 2018


  • Aromatase inhibitors
  • Estrogen receptor–positive breast cancer
  • Neoadjuvant chemotherapy
  • Neoadjuvant endocrine therapy


Dive into the research topics of 'Neoadjuvant Endocrine Therapy: Who Benefits Most?'. Together they form a unique fingerprint.

Cite this